what is merck doing with cavatac, page-3

  1. 255 Posts.
    lightbulb Created with Sketch. 35

    For those of us still following the progress of Cavatak, Merck is presenting the results of the KEYNOTE 200 trial at ESMO18 on the 20th Oct.


    LBA40 - Phase 1b KEYNOTE-200. A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

    Presentation Number LBA40

    Lecture Time17:15 - 17:15

    Speakers Charles M. Rudin (New York, US)


    http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=lba40



    Last edited by DavieJones: 19/10/18
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.